Polyrizon Stock Soars 37.93% on Nasal Allergy Breakthrough

On July 23, 2025, Polyrizon's stock surged by 37.93% in pre-market trading, marking a significant rise in investor confidence.

Polyrizon's recent success in intranasal delivery of its PL-14 formulation has been a major driver of its stock price. The formulation achieved over 60% deposition in the nasal vestibule, the first physiological region exposed to airborne allergens, indicating its potential as an effective nasal allergy blocker.

This breakthrough has garnered significant attention from investors, with the company's stock surging following the announcement of the successful test results. The positive market response reflects the potential of Polyrizon's technology in addressing allergic rhinitis, a common and debilitating condition.

Additionally, Polyrizon's successful safety study of the PL-14 formulation in a human nasal tissue model further solidifies its position as a leader in nasal allergy treatment. The study's positive outcomes have reinforced investor confidence in the company's innovative approach to allergy management.